Local company’s new MS treatment shows promising trial results
Following a five-year study, Genzyme announced that its newest multiple sclerosis treatment has significantly improved the symptoms of most patients within the trial, The Boston Business Journal reported.
The Cambridge-based biotech company says it’s too soon to say if the drug, Lemtrada, is a cure for MS. Results have shown, however, that 60 percent of patients saw fewer symptoms and did not need additional treatment after first receiving the drug, according to the BBJ.
Unlike most neurodegenerative disease treatments that must be taken daily, Lemtrada is administered to patients for five days, and then for another three days a year later.
Read the full BBJ report here.
Related gallery: Famous Massachusetts companies
[bdc-gallery id=”467115″]
To comment, please create a screen name in your profile
To comment, please verify your email address
Conversation
This discussion has ended. Please join elsewhere on Boston.com